You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Infigratinib

Showing 1 - 23 of 23
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cholangiocarcinoma, Liver Cancer Trial in Houston (Infigratinib, Atezolizumab, Bevacizumab)

Not yet recruiting
  • Cholangiocarcinoma
  • Liver Cancer
  • Infigratinib
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Houston (drug, other, procedure)

Active, not recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Infigratinib
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 21, 2022

Achondroplasia Trial in Australia, Spain, United Kingdom (Infigratinib)

Recruiting
  • Achondroplasia
  • Infigratinib
  • Parkville, Victoria, Australia
  • +3 more
Apr 5, 2022

Achondroplasia Trial in Worldwide (Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg)

Recruiting
  • Achondroplasia
  • Infigratinib 0.016 mg/kg
  • +3 more
  • Oakland, California
  • +17 more
Apr 5, 2022

Glioma, Glioblastoma, GBM Trial in Chandler, Phoenix, Scottsdale (Infigratinib)

Recruiting
  • Glioma
  • +2 more
  • Infigratinib
  • Chandler, Arizona
  • +2 more
Mar 10, 2022

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Infigratinib
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Infigratinib
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)

Not yet recruiting
  • Advanced Solid Tumor
  • +2 more
  • Infigratinib
  • Palo Alto, California
  • +9 more
Aug 2, 2022

Bladder Transitional Cell Carcinoma, Bladder Cancer, Fibroblast Growth Factor Receptor Trial (Infigratinib)

Withdrawn
  • Bladder Transitional Cell Carcinoma
  • +2 more
  • Infigratinib
  • (no location specified)
Aug 8, 2022

Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8, Stage I Intrahepatic

Not yet recruiting
  • Resectable Intrahepatic Cholangiocarcinoma
  • +4 more
  • Atlanta, Georgia
  • +2 more
Aug 19, 2022

Advanced Cholangiocarcinoma, FGFR2 Gene Mutation Trial in Worldwide (BGJ398, Gemcitabine, Cisplatin)

Active, not recruiting
  • Advanced Cholangiocarcinoma
  • FGFR2 Gene Mutation
  • Gilbert, Arizona
  • +115 more
Oct 17, 2022

Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer Trial in Worldwide (Infigratinib, Placebo)

Recruiting
  • Upper Tract Urothelial Carcinomas
  • Urothelial Bladder Cancer
  • Infigratinib
  • Placebo
  • Tucson, Arizona
  • +133 more
Apr 25, 2022

FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification Trial in Chicago (BGJ398)

Terminated
Has Results
  • FGFR Gene Amplification
  • +9 more
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
Apr 9, 2019

Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma Trial in New York (BGJ398)

Active, not recruiting
  • Bladder Cancer
  • Non-Muscle-Invasive Urothelial Carcinoma
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 3, 2022

Melanoma Trial in Worldwide (LGX818, MEK162, LEE011)

Active, not recruiting
  • Melanoma
  • Los Angeles, California
  • +31 more
Jun 11, 2021

Tumor With Alterations of the FGF-R Trial in China, Japan (BGJ398)

Completed
  • Tumor With Alterations of the FGF-R
  • Guangzhou, Guangdong, China
  • +7 more
Dec 6, 2020

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Worldwide (BGJ398, BYL719)

Completed
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Tampa, Florida
  • +21 more
Dec 6, 2020

Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3, Squamous Lung Cancer With FGFR1 Amplification, Bladder Cancer With

Completed
  • Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3
  • +5 more
  • Duarte, California
  • +49 more
Oct 2, 2019

Tumor-Induced Osteomalacia, Oncogenic Osteomalacia Trial run by the NIDCR (BGJ398)

Terminated
Has Results
  • Tumor-Induced Osteomalacia
  • Oncogenic Osteomalacia
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Mar 15, 2021

Advanced Gastrointestinal Stromal Tumor (GIST) Trial in United States (BGJ398, Imatinib Mesylate)

Completed
Has Results
  • Advanced Gastrointestinal Stromal Tumor (GIST)
  • Boston, Massachusetts
  • +6 more
Mar 16, 2020

Solid Tumor, Hematologic Malignancies Trial in United States (BGJ398)

Terminated
Has Results
  • Solid Tumor
  • Hematologic Malignancies
  • Birmingham, Alabama
  • +55 more
May 28, 2019

Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Trial in Buffalo (Fluorouracil, Irinotecan

Withdrawn
  • Colon Adenocarcinoma
  • +16 more
  • Buffalo, New York
    Roswell Park Cancer Institute
May 19, 2016

Cancer of Cervix, Tumors Trial (BGJ398, Carboplatin, Paclitaxel)

Withdrawn
  • Cancer of Cervix
  • Tumors
  • (no location specified)
Feb 13, 2015